CohBar Announces Reverse Stock Split
MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01am ET on September 23, 2022 and begin trading on a split-adjusted basis at the market open on September 23, 2022 with the new CUSIP number 19249J 307.
Related news for (CWBR)
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FRGI, CWBR, SCU
- COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. – CWBR
- CohBar Reports Second Quarter 2023 Financial Results